Small Cap Biotech January/Febuary 2010 FDA Decision Dates

Below is a list of Small cap biotech January and February FDA decision dates – and the publicly traded companies that could see a price movement in their share prices as those dates approach, wheather is up or down all depending upon the decition. Good luck!

FDA decision due: Jan. 16, 2010
MannKind Corporation (NASDAQ:MNKD)
Regarding: Preliminary approval an inhaled insulation device called Afresa.
Share price as of 12/30/2009: $25.40

FDA decision due: Jan. 18, 2010
Roche Holding Ltd. (OTC:RHHBY)
Regarding: Approval for the use of Taceva for the treatment of lung cancer in patients already responding to chemotherapy.
Share price as of 12/30/2009: $42.18

FDA decision due: Jan. 22, 2010
Acorda Therapeutics (NASDAQ:ACOR)
Regarding: New drug application review for Fampridine-SR to be used to improve conduction in nerve fibers when the insulating layer (myelin) has been damaged.
Share price as of 12/30/2009: $25.39

FDA decision due: Jan. 30, 2010
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Regarding: The results of a meeting with the FDA to discuss the viability of continuing to seek approval for Fusilev for the treatment of colon cancer will be announced.
Share price as of 12/30/2009: $4.42

FDA decision due: Feb. 9, 2009
XenoPort, Inc. (NASDAQ:XNPT)
Regarding: FDA review results of gabapentin encarbil for the treatment of moderate-to-severe primary Restless Legs Syndrome.
Share price as of 12/30/2009: $18.48

FDA decision due: Feb. 11, 2009
Labopharm Inc. (NASDAQ:DDSS)
Regarding: Approval of Trazodone Contramid for depression.
Share price as of 12/30/2009: $2.03

FDA decision due: Feb. 12, 2009
Cadance Pharmaceuticals (NASDAQ:CADX)
Regarding: Approval of acetavance (intravenous acetamenophin) for the treatment of fever and pain.
Share price as of 12/30/2009: $9.73

FDA decision due: Feb. 13, 2009
Gilead Sciences (NASDAQ:GILD)
Regarding: Approval of Cayston for the treatment of cystic fibrosis.
Share price as of 12/30/2009: $43.93

FDA decision due: Feb. 28, 2009
Shire Pharmaceuticals (NASDAQ:SHPGY)
Regarding: Approval of velaglucerase to treat Gaucher’s disease (a genetic condition that causes fat buildups around internal organs).
Share price as of 12/30/2009: $58.20